218450-16-9

Basic information

• Product Name: (+)-4(S)-(3,4-Difluorophenyl)-N-[3-[4-(4-fluorophenyl)piperidin-1-yl]propyl]-5(S)-methyl-2-oxooxazolidine-3-carboxamide
• Synonyms: SNAP-7915
• CAS NO: 218450-16-9
• Molecular Formula: C₂₅H₂₈F₃N₃O₃
• Molecular Weight: 475.51541
• Mol File: 218450-16-9.mol

Chemical Properties

• CAS DataBase Reference: (+)-4(S)-(3,4-Difluorophenyl)-N-[3-[4-(4-fluorophenyl)piperidin-1-yl]propyl]-5(S)-methyl-2-oxooxazolidine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-4(S)-(3,4-Difluorophenyl)-N-[3-[4-(4-fluorophenyl)piperidin-1-yl]propyl]-5(S)-methyl-2-oxooxazolidine-3-carboxamide(218450-16-9)
• EPA Substance Registry System: (+)-4(S)-(3,4-Difluorophenyl)-N-[3-[4-(4-fluorophenyl)piperidin-1-yl]propyl]-5(S)-methyl-2-oxooxazolidine-3-carboxamide(218450-16-9)

Safety Data

• Hazardous Substances Data: 218450-16-9(Hazardous Substances Data)

Upstream product

• 218450-10-3 4(S)-(3,4-difluorophenyl)-5(S)-methyloxazolidin-2-one 
• 75-09-2 dichloromethane 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 218450-04-5 [1-(3,4-difluorophenyl)-2-hydroxypropyl]carbamic acid tert-butyl ester 
• 218450-03-4 1-amino-1-(3,4-difluoro-phenyl)-propan-2-ol 
• 218450-02-3 1-(3,4-difluorophenyl)-2-hydroxy-propan-1-one-oxime 
• 218450-01-2 1-(3,4-difluorophenyl)-2-hydroxy-propan-1-one 
• 245046-55-3 3-[4-(4-Fluoro-phenyl)-piperidin-1-yl]-propylamine 
• 328387-93-5 (2S)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-(3,4-difluorophenyl)-1-propanone oxime 
• 328387-94-6 (S)-1-Amino-1-(3,4-difluoro-phenyl)-propan-2-ol 
• 328557-42-2 4-nitrophenyl(4R,5S)-4-(3,4-difluorophenyl)-5-methyl-2-oxo-1,3-oxazolidine-3-carboxylate 
• 218450-05-6 (4S,5S)-4-(3,4-difluorophenyl)-5-methyloxazolidin-2-one 
• 530-62-1 1,1'-carbonyldiimidazole 
• 245046-56-4 3-[4-(4-fluorophenyl)piperidin-1-yl] propylphthalimide 

Relevant articles and documents

Combination therapy for the treatment of benign prostatic hyperplasia

This invention relates to combination therapy for the treatment of benign prostatic hyperplasia comprising an alpha-1a antagonist and an endothelin antagonist. More specifically, the use of a selective alpha-1a adrenergic receptor antagonist in combination with a subtype non-selective endothelin antagonist provides relief of lower urinary tract symptoms in patients with symptomatic prostatism or benign prostatic hyperplasia. This combination therapy improves lower urinary tract symptoms including increasing urine flow rate, decreasing residual urine volume and improving overall obstructive and irritative symptoms in patients with benign prostatic hyperplasia or symptomatic prostatism.

Process for preparing β-hydroxycarbamates and their conversion to oxazolidinones

A process for preparing a β-hydroxy carbamate product is disclosed. The process comprises reacting an olefin compound containing at least one carbon-carbon double bond with a carbamate in an aqueous solvent and in the presence of a base, an osmium catalys

Crystalline pharmaceutically acceptable salts of an oxazolidinone derivative

A crystalline pharmaceutically acceptable benzenesulfonate salt of Compound A of formula: and solvates thereof are disclosed. Compound A and its benzenesulfonate salts are alpha 1a adrenergic receptor antagonists useful in the treatment of benign prostati

Determination of the relative and absolute stereochemistry of a potent and α(1A)-selective adrenoceptor antagonist

The binding affinities and selectivities of antagonists 1-4 for the α(1A)-adrenoceptor are dependent on the stereochemical orientation of the groups at the C-4 and C-5 positions of the oxazolidinone ring. The unambiguous assignment of the relative and abs

Oxazolidinones as alpha 1A receptor antagonists

This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.